Automatic Sign Language Translation for Healthcare Websites
Automatic Sign Language Translation for Healthcare Websites
批准号:
10044419
负责人:
金额:
$4.91万
依托单位:
依托单位国家:
英国
项目类别:
Grant for R&D
财政年份:
2022
资助国家:
英国
项目状态:
已结题
起止时间:
2022 至 --
中文摘要
英国每天约有87,000人使用英国手语(BSL)。只有1%的网站被认为是这些人可以访问的(RNID,2018)。聋人的识字率往往很低,很难理解书面英语。传统的解决方案是使用BSL解释器,使聋人能够理解重要信息。然而,英国只有1000名口译员,这意味着平均需要等待大约两天的口译。其结果是公共服务和聋人之间的沟通障碍,需要获得信息,特别是与医疗保健的斗争。研究表明,聋人的健康状况已经比听力正常的人差得多,其中信息的可获得性是一个主要因素(SignHealth,2020)。在线可访问性甚至更低,医疗保健网站上几乎没有签名内容的例子。主要原因是雇佣口译员签署所有内容的成本,每小时180英镑的翻译成本是不可行的。在这个项目中,Signapse将研究为医疗网站构建自动手语翻译技术的可行性。在20年计算研究的支持下,Signapse的使命是将人工智能和手语结合在一起。Signapse是在一些主要组织接触后成立的,这些组织希望提供实时和更便宜的BSL口译员替代品。我们开发了世界领先的创新技术,深受聋人社区的欢迎。我们的下一个开发阶段是研究用于医疗保健等受限领域的创新翻译方法。医疗保健网站是开发我们翻译技术的理想场所,因为它既是一个有用的应用程序,也是一个需要较少数据处理的受限领域。在拟议的项目中,我们将进行可行性研究,以评估技术要求,了解任务并为市场制定商业化计划。由于这项技术涉及很大程度的创新,我们认为在我们走向商业成功的道路上催化进一步的创新之前,首先确定市场范围是很重要的。如果这个项目成功,它将使更多的聋人在线访问,这意味着他们可以更好地了解医疗保健内容和在线访问自助材料,特别是有关心理健康和福祉。这将提高他们进行自我护理的能力,而不依赖于人类的解释。我们相信这个项目将大大改善所有BSL用户的健康。
英文摘要
There are approximately 87,000 people who use British Sign Language (BSL) daily in the UK. Only 1% of websites are considered accessible to these people (RNID, 2018). Deaf people often have poor literacy rates and struggle to understand written English. The traditional solution is to use a BSL Interpreter to enable Deaf people to understand important information. However, there are only 1000 interpreters in the UK; meaning a lengthy wait for interpretation of about two days on average. The result is a communication barrier between public services and Deaf people that need access to information, with a particular struggle with healthcare. Research has shown that Deaf people's health is already much poorer than hearing people's, with accessibility to information a major factor in this (SignHealth, 2020). Accessibility is even lower online, with almost no examples of signed content on healthcare websites. The main reason is the cost of hiring interpreters to sign all the content, with a £180 an hour translation cost infeasible. In this project, Signapse will scope the feasibility of building automatic sign language translation technology for healthcare websites. Backed by 20 years of computational research, Signapse's mission is to bring AI and sign language together. Signapse was founded after being approached by major organisations that wanted a real-time and cheaper alternative to BSL interpreters. We have developed world-leading innovative technology that is well received by the Deaf community. Our next development phase is to investigate innovative translation methodologies for constrained domains such as healthcare. Healthcare websites are an ideal place to develop our translation technology, as it is both a useful application but also a constrained domain which requires less data to tackle. Within the proposed project, we shall conduct a feasibility study to assess the requirements of the technology, understand the task and enable a commercialisation plan for the market. Due to the large degree of innovation involved with this technology, we believe it is important to first scope the market before we catalyse further innovation on our path to commercial success. If this project is successful, it will enable more accessibility for Deaf people online, meaning they can better understand healthcare content and access self help materials online, particularly pertaining to mental health and wellbeing. This will increase their ability to perform self-care, without relying on human interpretation. We believe this project will significantly improve the health of all BSL users.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
国内基金
海外基金
登录
查看更多内容
基于BCG载药系统靶向抑制DC-SIGN阳性肿瘤相关巨噬细胞增强脾胱癌免疫治疗的应用及机制研究
-
批准号:--
-
项目类别:青年科学基金项目
-
资助金额:--
-
批准年份:2024
-
负责人:刘康
-
依托单位:
局灶节段硬化性肾小球肾炎中FSTL3通过DC-SIGN促足细胞凋亡的作用研究
-
批准号:82300796
-
项目类别:青年科学基金项目
-
资助金额:30万元
-
批准年份:2023
-
负责人:林力
-
依托单位:
DC-SIGN阳性肿瘤相关巨噬细胞通过诱导Th22细胞亚群分化促进膀胱癌免疫逃逸的机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:许乐
-
依托单位:
DC-SIGN+肿瘤相关巨噬细胞发生及促肌层浸润性膀胱癌免疫逃逸的机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:胡宝英
-
依托单位:
DC-SIGN/R靶向糖纳米抑制剂开发及结构机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2021
-
负责人:
-
依托单位:
RORγt+调节性T细胞参与DC-SIGN+肿瘤相关巨噬细胞介导的胃癌免疫逃逸过程的作用和机制研究
-
批准号:82003019
-
项目类别:青年科学基金项目
-
资助金额:24.0万元
-
批准年份:2020
-
负责人:李鹤
-
依托单位:
RA成纤维样滑膜细胞DC-SIGN在B细胞活化中的作用及其临床意义
-
批准号:82001742
-
项目类别:青年科学基金项目
-
资助金额:24.0万元
-
批准年份:2020
-
负责人:石茂华
-
依托单位:
LeX检查点通过DC-SIGN信号轴介导T细胞抑制和肿瘤浸润促进白血病免疫逃逸的机制研究
-
批准号:32060218
-
项目类别:地区科学基金项目
-
资助金额:37.0万元
-
批准年份:2020
-
负责人:李红
-
依托单位:
CSF-1诱导的DC-SIGN+巨噬细胞在子宫内膜异位症免疫抑制过程中的作用
-
批准号:81801417
-
项目类别:青年科学基金项目
-
资助金额:21.0万元
-
批准年份:2018
-
负责人:安敏
-
依托单位:
DC-SIGN介导的免疫调控在真菌性角膜炎发病机制中的研究
-
批准号:81870632
-
项目类别:面上项目
-
资助金额:57.0万元
-
批准年份:2018
-
负责人:赵桂秋
-
依托单位: